CN Patent

CN110256408B — 一种二芳基吡唑化合物及包含该化合物的组合物及其用途

Assigned to Shenzhen Targetrx Inc · Expires 2022-03-22 · 4y expired

What this patent protects

本发明提供了一种二芳基吡唑化合物及包含该化合物的组合物及其用途，所述的二芳基吡唑化合物如式(I)所示化合物或其互变异构体、立体异构体、前药、晶型、药学上可接受的盐、水合物或溶剂化合物。本发明化合物和组合物可用于治疗BRAF激酶突变的增殖性疾病且具有更优良的药代动力学性质。

USPTO Abstract

本发明提供了一种二芳基吡唑化合物及包含该化合物的组合物及其用途，所述的二芳基吡唑化合物如式(I)所示化合物或其互变异构体、立体异构体、前药、晶型、药学上可接受的盐、水合物或溶剂化合物。本发明化合物和组合物可用于治疗BRAF激酶突变的增殖性疾病且具有更优良的药代动力学性质。

Drugs covered by this patent

Patent Metadata

Patent number
CN110256408B
Jurisdiction
CN
Classification
—
Expires
2022-03-22
Drug substance claim
No
Drug product claim
No
Assignee
Shenzhen Targetrx Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.